Journal Article Epublish 3 citations
PubMed: 39902239 DOI: 10.1136/bmjmed-2024-001074
Comparative effectiveness of monovalent XBB.1.5 containing covid-19 mRNA vaccines in Denmark, Finland, and Sweden: target trial emulation based on registry data.
BMJ Med 3(1):e001074
Authors: Niklas Worm Andersson, Emilia Myrup Thiesson, Nicklas Pihlström, Jori Perälä, Kristýna Faksová, Mie Agermose Gram, Eero Poukka, Tuija Leino, Rickard Ljung, Anders Hviid
Affiliations
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
- Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden.
- Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
- Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
- Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
- Pharmacovigilance Research Centre, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
MeSH
Registries, Vaccines, Incidence, Covid-19 Vaccines, Rna, Messenger, Vaccination, Aged, Covid-19, Mrna Vaccines
Cited by
- The Mirror of Erised: a retrospective population-wide study of Czech all-cause mortality data by COVID-19 vaccination status. BMC Public Health, 2025
- XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants. Front Immunol, 2025
- Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024. Influenza Other Respir Viruses, 2025